On February 23, Lepu Biopharma Co., Ltd. was listed on Hong Kong Exchanges and Clearing Limited (HKEX), stock code: 2157.HK. The issue price is HKD 7.13 per share, and public offering raised about HKD 900 million.

Lepu Biopharma is an innovation-driven biopharmaceutical company focusing on oncology therapeutics with a strong China root and global vision. They have developed a strong oncology-focused pipeline of drug candidates, including ADCs, oncolytic virus drugs and immunotherapies at clinical and pre-clinical stages. They plan to commercialize our pipeline products in China through dedicated sales and marketing forces and in overseas markets, such as the U.S. and European markets, via partnerships.

Dr. Pu Zhongjie, Founder, Chairman and Executive Director of Lepu Biopharma, said: "The Lepu Biopharma listed on the HKEK is an important milestone in the history of the company's development. Our initial plan is to achieve our own cash flow in two to three years; secondly, to have 1-2 ADC indications approved in China; and thirdly, we hope that our differentiated products, including the combination of ADC and PD-1, can make a breakthrough in the international market.

With the official listing of the company on the HKEK, Lepu Biopharma will further promote international development.